Show simple item record

dc.contributor.authorGe, W
dc.contributor.authorClendenen, TV
dc.contributor.authorAfanasyeva, Y
dc.contributor.authorKoenig, KL
dc.contributor.authorAgnoli, C
dc.contributor.authorBrinton, LA
dc.contributor.authorDorgan, JF
dc.contributor.authorEliassen, AH
dc.contributor.authorFalk, RT
dc.contributor.authorHallmans, G
dc.contributor.authorHankinson, SE
dc.contributor.authorHoffman-Bolton, J
dc.contributor.authorKey, TJ
dc.contributor.authorKrogh, V
dc.contributor.authorNichols, HB
dc.contributor.authorSandler, DP
dc.contributor.authorSchoemaker, MJ
dc.contributor.authorSluss, PM
dc.contributor.authorSund, M
dc.contributor.authorSwerdlow, AJ
dc.contributor.authorVisvanathan, K
dc.contributor.authorLiu, M
dc.contributor.authorZeleniuch-Jacquotte, A
dc.date.accessioned2018-01-04T12:21:37Z
dc.date.issued2018-06-01
dc.identifier.citationInternational journal of cancer, 2018, 142 (11), pp. 2215 - 2226
dc.identifier.issn0020-7136
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/989
dc.identifier.eissn1097-0215
dc.identifier.doi10.1002/ijc.31249
dc.description.abstractA strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case-control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on age at blood donation. AMH was measured using a high sensitivity enzyme-linked immunoabsorbent assay. Conditional logistic regression was applied to the aggregated dataset. There was a statistically significant trend of increasing breast cancer risk with increasing AMH concentration (ptrend across quartiles <0.0001) after adjusting for breast cancer risk factors. The odds ratio (OR) for breast cancer in the top vs. bottom quartile of AMH was 1.60 (95% CI = 1.31-1.94). Though the test for interaction was not statistically significant (pinteraction  = 0.15), the trend was statistically significant only for tumors positive for both estrogen receptor (ER) and progesterone receptor (PR): ER+/PR+: ORQ4-Q1  = 1.96, 95% CI = 1.46-2.64, ptrend <0.0001; ER+/PR-: ORQ4-Q1  = 0.82, 95% CI = 0.40-1.68, ptrend  = 0.51; ER-/PR+: ORQ4-Q1  = 3.23, 95% CI = 0.48-21.9, ptrend  = 0.26; ER-/PR-: ORQ4-Q1  = 1.15, 95% CI = 0.63-2.09, ptrend  = 0.60. The association was observed for both pre- (ORQ4-Q1 = 1.35, 95% CI = 1.05-1.73) and post-menopausal (ORQ4-Q1  = 1.61, 95% CI = 1.03-2.53) breast cancer (pinteraction  = 0.34). In this large consortium study, we confirmed that AMH is associated with breast cancer risk, with a 60% increase in risk for women in the top vs. bottom quartile of AMH.
dc.formatPrint-Electronic
dc.format.extent2215 - 2226
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectLogistic Models
dc.subjectOdds Ratio
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subjectCase-Control Studies
dc.subjectProspective Studies
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectAnti-Mullerian Hormone
dc.titleCirculating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.
dc.typeJournal Article
dcterms.dateAccepted2017-12-07
rioxxterms.funderThe Institute of Cancer Research
rioxxterms.identifier.projectUnspecified
rioxxterms.versionofrecord10.1002/ijc.31249
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfInternational journal of cancer
pubs.issue11
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.publication-statusPublished
pubs.volume142
pubs.embargo.termsNot known
icr.researchteamAetiological Epidemiology
dc.contributor.icrauthorSchoemaker, Minouk
dc.contributor.icrauthorSwerdlow, Anthony


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record